Mon, July 30, 2018

Robyn Karnauskas Maintained (VRTX) at Strong Buy with Increased Target to $206 on, Jul 30th, 2018

Robyn Karnauskas of Citigroup, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $203 to $206 on, Jul 30th, 2018.

Robyn has made no other calls on VRTX in the last 4 months.



There are 2 other peers that have a rating on VRTX. Out of the 2 peers that are also analyzing VRTX, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018


This is the rating of the analyst that currently disagrees with Robyn


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018